Tolerability and safety of apomorphine SL (Ixense™)

Research output: Contribution to journalArticlepeer-review


Apomorphine SL (Ixense™) (apo SL) is a dopamine receptor agonist that can enhance sexual function in patients with erectile dysfunction (ED). For a patient, the ability to achieve a physiological erection, tolerability, efficacy and the speed of onset of the therapy are of considerable importance when considering ED treatment. Recent studies have focused on determining the patient's tolerability to apo SL as a therapy for ED. In addition, the cardiovascular profile of those patients that would be likely to receive apo SL in the clinic has been assessed. These studies have shown that apo SL is safe and effective in the treatment of ED and offers a new therapeutic option for the first-line treatment of patients with different concomitant diseases including cardiovascular disease and diabetes. The most frequently reported adverse events were nausea and dizziness, but no major adverse events have been noted in any of the clinical trials.

Original languageEnglish
JournalInternational Journal of Impotence Research
Issue numberSUPPL. 2
Publication statusPublished - Apr 2003


  • Apomorphine SL
  • Efficacy
  • Erectile dysfunction
  • Safety
  • Tolerability

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Tolerability and safety of apomorphine SL (Ixense™)'. Together they form a unique fingerprint.

Cite this